Pharmaceutical

Takeda’s ADZYNMA gains EU approval for cTTP treatment

The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).

Aug 9, 2024 - 04:00
Takeda’s ADZYNMA gains EU approval for cTTP treatment
The European Commission (EC) has approved Takeda's ADZYNMA (recombinant ADAMTS13) for congenital thrombotic thrombocytopenic purpura (cTTP).
Read the original article

Tags:

Previous Article

Bavarian Nordic tops up US smallpox/mpox vaccine stockpile with $156.8m order

Next Article

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Rise in cancer among younger people worries and puzzles doctors

STAT+: Rise in cancer among younger people worries and ...

Jul 24, 2023

Tierra raises $11.4 in Series A round for predictive AI protein maker

Tierra raises $11.4 in Series A round for predictive AI...

Mar 13, 2024

Oesophageal cancer: the global clinical trials landscape in 2024

Oesophageal cancer: the global clinical trials landscap...

Aug 29, 2024